Seikagaku reported FY 4Q20 orthopedic revenue of USD $32.3 million, +31.8% vs. FY 4Q19 with full-year FY 2020 revenue of $125.3 million, -9.6% vs. 2019. The company’s fourth quarter, ending March 31, showed substantial sequential improvement but couldn’t offset the impact of drug price reductions in Japan and pandemic-related decreases in outpatient services. The company continues to take share among single injection viscosupplements in the U.S. and sees a definitive recovery trend there.
Seikagaku forecasted total FY 2021 sales growth of +16.1% vs. 2020, driven partly by the introduction of JOYCLU, an injection treatment for osteoarthritis of the knee and hip. The drug is approved in Japan and pending a Phase III study in the United States.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q20
4Q19
$ Chg
% Chg
Orthobiologics
$32.3
$24.5
$7.8
31.8%
FY20
FY19
$ Chg
% Chg
Orthobiologics
$125.3
$138.6
($13.3)
(9.6%)
Geographic Sales
4Q20
4Q19
$ Chg
% Chg
Domestic (Japan)
$11.1
$10.2
$0.9
8.7%
International
$21.3
$14.4
$6.9
48.2%
Total
$32.3
$24.5
$7.8
31.8%
FY20
FY19
$ Chg
% Chg
Domestic (Japan)
$55.4
$63.0
($7.6)
(12.1%)
International
$69.9
$75.6
($5.7)
(7.5%)
Total
$125.3
$138.6
($13.3)
(9.6%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
Seikagaku reported FY 4Q20 orthopedic revenue of USD $32.3 million, +31.8% vs. FY 4Q19 with full-year FY 2020 revenue of $125.3 million, -9.6% vs. 2019. The company’s fourth quarter, ending March 31, showed substantial sequential improvement but couldn’t offset the impact of drug price reductions in Japan and pandemic-related decreases in...
Seikagaku reported FY 4Q20 orthopedic revenue of USD $32.3 million, +31.8% vs. FY 4Q19 with full-year FY 2020 revenue of $125.3 million, -9.6% vs. 2019. The company’s fourth quarter, ending March 31, showed substantial sequential improvement but couldn’t offset the impact of drug price reductions in Japan and pandemic-related decreases in outpatient services. The company continues to take share among single injection viscosupplements in the U.S. and sees a definitive recovery trend there.
Seikagaku forecasted total FY 2021 sales growth of +16.1% vs. 2020, driven partly by the introduction of JOYCLU, an injection treatment for osteoarthritis of the knee and hip. The drug is approved in Japan and pending a Phase III study in the United States.
Revenue Data
All revenue data is provided in USD millions unless otherwise noted. Sales and growth rates are estimated on an as-reported basis.
Segment Sales
4Q20
4Q19
$ Chg
% Chg
Orthobiologics
$32.3
$24.5
$7.8
31.8%
FY20
FY19
$ Chg
% Chg
Orthobiologics
$125.3
$138.6
($13.3)
(9.6%)
Geographic Sales
4Q20
4Q19
$ Chg
% Chg
Domestic (Japan)
$11.1
$10.2
$0.9
8.7%
International
$21.3
$14.4
$6.9
48.2%
Total
$32.3
$24.5
$7.8
31.8%
FY20
FY19
$ Chg
% Chg
Domestic (Japan)
$55.4
$63.0
($7.6)
(12.1%)
International
$69.9
$75.6
($5.7)
(7.5%)
Total
$125.3
$138.6
($13.3)
(9.6%)
Mike Evers is ORTHOWORLD’s Digital Content Strategist. He can be reached by email.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
Copy to clipboard 
